Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 4/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 10/20 | 0.43 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472400 | 0.89 | CAMK2D (0.46) | CAMK2DADORA2AADORA2BADORA1PDE4B | |
| SCHEMBL3472403 | 0.83 | RXRA (0.47) | CAMK2DADORA2AADORA2BADORA1PDE4B | |
| SCHEMBL3473978 | 0.75 | RXRA (0.53) | NFKB1NFKB2RELAMALT1MAPK8 | |
| SCHEMBL26378205 | 0.71 | HPGD (0.59) | — | |
| SCHEMBL3474803 | 0.70 | RXRA (0.52) | RAD52NFKB1NFKB2RELAMALT1 | |
| SCHEMBL24061106 | 0.69 | UTS2R (0.59) | CAMK2DFYN | |
| SCHEMBL3471994 | 0.68 | RXRA (0.51) | — | |
| SCHEMBL3472491 | 0.67 | RXRA (0.56) | — | |
| SCHEMBL13060639 | 0.67 | FYN (0.55) | CAMK2DRAD52FYN | |
| SCHEMBL3131821 | 0.67 | MAP4K4 (0.52) | CAMK2DRAD52FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | CAMK2D 3216/4885ADORA2A 455/4885ADORA2B 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.